Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 14/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20476784 | 0.89 | TXNRD1 (0.57) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL20471446 | 0.87 | TXNRD1 (0.50) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL10697700 | 0.83 | TDP1 (0.47) | MAPTNPSR1TXNRD1TDP1ALDH1A1 | |
| SCHEMBL10698683 | 0.81 | TDP1 (0.44) | MAPTNPSR1TXNRD1TDP1ALDH1A1 | |
| SCHEMBL10695727 | 0.81 | TDP1 (0.42) | MAPTMAPK1NPSR1TXNRD1TDP1 | |
| SCHEMBL10697029 | 0.81 | TDP1 (0.42) | MAPTNPSR1TXNRD1TDP1ALDH1A1 | |
| SCHEMBL10697848 | 0.78 | FGFR4 (0.45) | MAPTNPSR1TXNRD1TDP1ALDH1A1 | |
| SCHEMBL20471448 | 0.78 | CYP3A4 (0.39) | MAPTMAPK1NPSR1TXNRD1TDP1 | |
| SCHEMBL10699015 | 0.77 | TDP1 (0.42) | MAPTMAPK1HTTTXNRD1TDP1 | |
| SCHEMBL10698436 | 0.77 | MEN1 (0.43) | MAPTNPSR1HTTTXNRD1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | claimed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | claimed |
| WO-2018146472-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2018-08-16 | — | — | WO | claimed |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| EP-3752151-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Cinda Pharma AB (SE) | 2020-12-23 | — | — | EP | disclosed |
| CN-111867587-A | Thioredoxin reductase inhibitors for the treatment of cancer | 信达制药公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
| WO-2019155086-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2019-08-15 | — | — | WO | disclosed |
| WO-2018146472-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2018-08-16 | — | — | WO | disclosed |
| EP-0272533-A2 | Substituted phenoxypyridines | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | S1PR4 919/4885MAPT 4656/4885S1PR1 571/4885 |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | S1PR4 919/4885MAPT 4656/4885S1PR1 571/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | S1PR4 919/4885MAPT 4656/4885S1PR1 571/4885 |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | TXNRD3, TXNRD1, TXNRD2 | S1PR4 391/4885MAPT 3571/4885S1PR1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.